Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 201-215

  Lupo, Barbara ^a,b   Trusolino, Livio ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

BRCAness; DNA repair; Poly(ADP ribose) polymerase; Synthetic lethality; Tankyrase; Targeted cancer therapies

Indexed keywords

AZD 2461; BMN 673; BRCA1 PROTEIN; BRCA2 PROTEIN; CEDIRANIB; CEP 9722; DINACICLIB; DNA; E 7016; E 7449; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMATINIB; INIPARIB; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PROTEIN P53; RUCAPARIB; TANKYRASE; TANKYRASE 1; TANKYRASE 2; TEMOZOLOMIDE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VELIPARIB; 3 AMINOBENZAMIDE; P53 BINDING PROTEIN 1; TALAZOPARIB;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; CANCER THERAPY; DNA DAMAGE; DNA REPAIR; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS INHIBITION; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; MONOTHERAPY; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; UNSPECIFIED SIDE EFFECT; UPREGULATION; ANGIOGENESIS; B CELL LYMPHOMA; BLADDER CANCER; BRAIN CANCER; CELL DEATH; COLORECTAL CANCER; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SAFETY; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME INHIBITION; ESOPHAGUS CANCER; EWING SARCOMA; EXCISION REPAIR; HOMOLOGOUS RECOMBINATION; IC50; IN VITRO STUDY; LEUKEMIA; LIVER CANCER; LUNG CANCER; LYMPHOMA; MISMATCH REPAIR; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHUMAN; PANCREAS CANCER; PERITONEUM CANCER; PROSTATE CANCER; RECTUM CANCER; SIGNAL TRANSDUCTION; SINGLE STRANDED DNA BREAK; STOMACH CANCER; TREATMENT OUTCOME; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; UTERUS CANCER;

BRCANESS; DNA REPAIR; POLY(ADP-RIBOSE) POLYMERASE; SYNTHETIC LETHALITY; TANKYRASE; TARGETED CANCER THERAPIES;

ADENOSINE DIPHOSPHATE RIBOSE; ANIMALS; ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84905251990     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.07.004     Document Type: Review

References (205)

1. Chambon P., Weill J.D., Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. 1963, 11:39-43.
2. Amé J.C., Spenlehauer C., de Murcia G. The PARP superfamily. Bioessays 2004, 26:882-893.
3. Schreiber V., Dantzer F., Ame J.C., de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7:517-528.
4. Weaver A.N., Yang E.S. Beyond DNA repair: additional functions of PARP-1 in cancer. Front. Oncol. 2013, 3:290.
5. Hottiger M.O., Hassa P.O., Lüscher B., Schüler H., Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem. Sci. 2010, 35:208-219.
6. Dantzer F., Amé J.C., Schreiber V., Nakamura J., Ménissier-de Murcia J., de Murcia G. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol. 2006, 409:493-510.
7. Ménissier de Murcia J., Ricoul M., Tartier L., Niedergang C., Huber A., Dantzer F., Schreiber V., Amé J.C., Dierich A., LeMeur M., Sabatier L., Chambon P., de Murcia G. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. 2003, 22:2255-2263.
8. Boehler C., Gauthier L.R., Mortusewicz O., Biard D.S., Saliou J.M., Bresson A., Sanglier-Cianferani S., Smith S., Schreiber V., Boussin F., Dantzer F. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2783-2788.
9. Fernández-Marcelo T., Frías C., Pascua I., de Juan C., Head J., Gómez A., Hernando F., Jarabo J.R., Díaz-Rubio E., Torres A.J., Rouleau M., Benito M., Iniesta P. Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity. J. Exp. Clin. Cancer Res. 2014, 33:19.
10. Riffell J.L., Lord C.J., Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat. Rev. Drug Discov. 2012, 11:923-936.
11. Vyas S., Chesarone-Cataldo M., Todorova T., Huang Y.H., Chang P. A systematic analysis of the PARP protein family identifies new functions critical for cell physiology. Nat. Commun. 2013, 4:2240.
12. Wooster R., Weber B.L. Breast and ovarian cancer. N. Engl. J. Med. 2003, 348:2339-2347.
13. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.
14. Nijman S.M., Friend S.H. Cancer. Potential of the synthetic lethality principle. Science 2013, 342:809-811.
15. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 2005, 5:689-698.
16. Lord C.J., Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 2008, 8:363-369.
17. McCabe N., Turner N.C., Lord C.J., Kluzek K., Bialkowska A., Swift S., Giavara S., O'Connor M.J., Tutt A.N., Zdzienicka M.Z., Smith G.C., Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006, 66:8109-8115.
18. Gelmon K.A., Tischkowitz M., Mackay H., Swenerton K., Robidoux A., Tonkin K., Hirte H., Huntsman D., Clemons M., Gilks B., Yerushalmi R., Macpherson E., Carmichael J., Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011, 12:852-861.
19. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
20. Fortini P., Pascucci B., Parlanti E., D'Errico M., Simonelli V., Dogliotti E. The base excision repair: mechanisms and its relevance for cancer susceptibility. Biochimie 2003, 85:1053-1071.
21. Stracker T.H., Petrini J.H. The MRE11 complex: starting from the ends. Nat. Rev. Mol. Cell Biol. 2011, 12:90-103.
22. Polo S.E., Jackson S.P. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev. 2011, 25:409-433.
23. Davis A.J., Chen D.J. DNA double strand break repair via non-homologous end-joining. Transl. Cancer Res. 2013, 2:130-143.
24. De Vos M., Schreiber V., Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem. Pharmacol. 2012, 84:137-146.
25. Bürkle A. Poly(ADP-ribose). The most elaborate metabolite of NAD+. FEBS J. 2005, 272:4576-4589.
26. Satoh M.S., Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature 1992, 356:356-358.
27. El-Khamisy S.F., Masutani M., Suzuki H., Caldecott K.W. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 2003, 31:5526-5533.
28. Caldecott K.W., Aoufouchi S., Johnson P., Shall S. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro. Nucleic Acids Res. 1996, 24:4387-4394.
29. Ström C.E., Johansson F., Uhlén M., Szigyarto C.A., Erixon K., Helleday T. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 2011, 39:3166-3175.
30. Liu Y., Kadyrov F.A., Modrich P. PARP-1 enhances the mismatch-dependence of 5'-directed excision in human mismatch repair in vitro. DNA Repair (Amst) 2011, 10:1145-1153.
31. Robu M., Shah R.G., Petitclerc N., Brind'Amour J., Kandan-Kulangara F., Shah G.M. Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:1658-1663.
32. Helleday T., Bryant H.E., Schultz N. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 2005, 4:1176-1178.
33. Bryant H.E., Petermann E., Schultz N., Jemth A.S., Loseva O., Issaeva N., Johansson F., Fernandez S., McGlynn P., Helleday T. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009, 28:2601-2615.
34. Wang M., Wu W., Rosidi B., Zhang L., Wang H., Iliakis G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006, 34:6170-6182.
35. Chen L., Nievera C.J., Lee A.Y., Wu X. Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J. Biol. Chem. 2008, 283:7713-7720.
36. Sy S.M., Huen M.S., Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7155-7160.
37. Liu J., Doty T., Gibson B., Heyer W.D. Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat. Struct. Mol. Biol. 2010, 17:1260-1262.
38. Deng C.X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006, 34:1416-1426.
39. Sandhu S.K., Yap T.A., de Bono J.S. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur. J. Cancer 2010, 46:9-20.
40. Curtin N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 2012, 12:801-817.
41. Curtin N.J. PARP inhibitors for cancer therapy. Expert Rev. Mol. Med. 2005, 7:1-20.
42. Furgason J.M., Bahassi e.M. Targeting DNA repair mechanisms in cancer. Pharmacol. Ther. 2013, 137:298-308.
43. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
44. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
45. Martin S.A., Lord C.J., Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr. Opin. Genet. Dev. 2008, 18:80-86.
46. Evers B., Helleday T., Jonkers J. Targeting homologous recombination repair defects in cancer. Trends Pharmacol. Sci. 2010, 31:372-380.
47. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 2008, 26:3785-3790.
48. Patel A.G., Sarkaria J.N., Kaufmann S.H. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3406-3411.
49. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol. 2011, 5:387-393.
50. Murai J., Huang S.Y., Das B.B., Renaud A., Zhang Y., Doroshow J.H., Ji J., Takeda S., Pommier Y. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012, 72:5588-5599.
51. Murai J., Huang S.Y., Renaud A., Zhang Y., Ji J., Takeda S., Morris J., Teicher B., Doroshow J.H., Pommier Y. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 2014, 13:433-443.
52. Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 2004, 4:814-819.
53. Dedes K.J., Wilkerson P.M., Wetterskog D., Weigelt B., Ashworth A., Reis-Filho J.S. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011, 10:1192-1199.
54. Weston V.J., Oldreive C.E., Skowronska A., Oscier D.G., Pratt G., Dyer M.J., Smith G., Powell J.E., Rudzki Z., Kearns P., Moss P.A., Taylor A.M., Stankovic T. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010, 116:4578-4587.
55. Vilar E., Bartnik C.M., Stenzel S.L., Raskin L., Ahn J., Moreno V., Mukherjee B., Iniesta M.D., Morgan M.A., Rennert G., Gruber S.B. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 2011, 71:2632-2642.
56. Min A., Im S.A., Yoon Y.K., Song S.H., Nam H.J., Hur H.S., Kim H.P., Lee K.H., Han S.W., Oh D.Y., Kim T.Y., O'Connor M.J., Kim W.H., Bang Y.J. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. Mol. Cancer Ther. 2013, 12:865-877.
57. Michels J., Vitale I., Saparbaev M., Castedo M., Kroemer G. Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene 2013, [Epub ahead of print]. 10.1038/onc.2013.352.
58. Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R., Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A., Lord C.J., Ashworth A., Reis-Filho J.S. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci. Transl. Med. 2010, 2:53ra75.
59. McEllin B., Camacho C.V., Mukherjee B., Hahm B., Tomimatsu N., Bachoo R.M., Burma S. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 2010, 70:5457-5464.
60. Mendes-Pereira A.M., Martin S.A., Brough R., McCarthy A., Taylor J.R., Kim J.S., Waldman T., Lord C.J., Ashworth A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 2009, 1:315-322.
61. Forster M.D., Dedes K.J., Sandhu S., Frentzas S., Kristeleit R., Ashworth A., Poole C.J., Weigelt B., Kaye S.B., Molife L.R. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat. Rev. Clin. Oncol. 2011, 8:302-306.
62. Shen W.H., Balajee A.S., Wang J., Wu H., Eng C., Pandolfi P.P., Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170.
63. Fraser M., Zhao H., Luoto K.R., Lundin C., Coackley C., Chan N., Joshua A.M., Bismar T.A., Evans A., Helleday T., Bristow R.G. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin. Cancer Res. 2012, 18:1015-1027.
64. Gupta A., Yang Q., Pandita R.K., Hunt C.R., Xiang T., Misri S., Zeng S., Pagan J., Jeffery J., Puc J., Kumar R., Feng Z., Powell S.N., Bhat A., Yaguchi T., Wadhwa R., Kaul S.C., Parsons R., Khanna K.K., Pandita T.K. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 2009, 8:2198-2210.
65. Hunt C.R., Gupta A., Horikoshi N., Pandita T.K. Does PTEN loss impair DNA double-strand break repair by homologous recombination?. Clin. Cancer Res. 2012, 18:920-922.
66. Shen Y., Rehman F.L., Feng Y., Boshuizen J., Bajrami I., Elliott R., Wang B., Lord C.J., Post L.E., Ashworth A. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin. Cancer Res. 2013, 19:5003-5015.
67. Anders C.K., Winer E.P., Ford J.M., Dent R., Silver D.P., Sledge G.W., Carey L.A. Poly(ADP-ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin. Cancer Res. 2010, 16:4702-4710.
68. Holstege H., Horlings H.M., Velds A., Langerød A., Børresen-Dale A.L., van de Vijver M.J., Nederlof P.M., Jonkers J. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer 2010, 10:654.
69. Turner N.C., Reis-Filho J.S., Russell A.M., Springall R.J., Ryder K., Steele D., Savage K., Gillett C.E., Schmitt F.C., Ashworth A., Tutt A.N. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007, 26:2126-2132.
70. Baldassarre G., Battista S., Belletti B., Thakur S., Pentimalli F., Trapasso F., Fedele M., Pierantoni G., Croce C.M., Fusco A. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol. Cell. Biol. 2003, 23:2225-2238.
71. Beger C., Pierce L.N., Kruger M., Marcusson E.G., Robbins J.M., Welcsh P., Welch P.J., Welte K., King M.C., Barber J.R., Wong-Staal F. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:130-135.
72. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., Gabrielson E., Schutte M., Baylin S.B., Herman J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 2000, 92:564-569.
73. Chalasani P., Livingston R. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist 2013, 18:909-916.
74. Hughes-Davies L., Huntsman D., Ruas M., Fuks F., Bye J., Chin S.F., Milner J., Brown L.A., Hsu F., Gilks B., Nielsen T., Schulzer M., Chia S., Ragaz J., Cahn A., Linger L., Ozdag H., Cattaneo E., Jordanova E.S., Schuuring E., Yu D.S., Venkitaraman A., Ponder B., Doherty A., Aparicio S., Bentley D., Theillet C., Ponting C.P., Caldas C., Kouzarides T. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003, 115:523-535.
75. C.G.A.R. Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
76. Rigakos G., Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 2012, 17:956-962.
77. Ström C.E., Helleday T. Strategies for the use of poly(adenosine diphosphate ribose) polymerase (PARP) Inhibitors in cancer therapy. Biomolecules 2012, 2:635-649.
78. Durkacz B.W., Omidiji O., Gray D.A., Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980, 283:593-596.
79. Curtin N.J., Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol. Aspects Med. 2013, 34:1217-1256.
80. Calabrese C.R., Almassy R., Barton S., Batey M.A., Calvert A.H., Canan-Koch S., Durkacz B.W., Hostomsky Z., Kumpf R.A., Kyle S., Li J., Maegley K., Newell D.R., Notarianni E., Stratford I.J., Skalitzky D., Thomas H.D., Wang L.Z., Webber S.E., Williams K.J., Curtin N.J. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 2004, 96:56-67.
81. Tentori L., Leonetti C., Scarsella M., D'Amati G., Vergati M., Portarena I., Xu W., Kalish V., Zupi G., Zhang J., Graziani G. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res. 2003, 9:5370-5379.
82. Donawho C.K., Luo Y., Penning T.D., Bauch J.L., Bouska J.J., Bontcheva-Diaz V.D., Cox B.F., DeWeese T.L., Dillehay L.E., Ferguson D.C., Ghoreishi-Haack N.S., Grimm D.R., Guan R., Han E.K., Holley-Shanks R.R., Hristov B., Idler K.B., Jarvis K., Johnson E.F., Kleinberg L.R., Klinghofer V., Lasko L.M., Liu X., Marsh K.C., McGonigal T.P., Meulbroek J.A., Olson A.M., Palma J.P., Rodriguez L.E., Shi Y., Stavropoulos J.A., Tsurutani A.C., Zhu G.D., Rosenberg S.H., Giranda V.L., Frost D.J. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 2007, 13:2728-2737.
83. Rouleau M., Patel A., Hendzel M.J., Kaufmann S.H., Poirier G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010, 10:293-301.
84. Plummer R., Jones C., Middleton M., Wilson R., Evans J., Olsen A., Curtin N., Boddy A., McHugh P., Newell D., Harris A., Johnson P., Steinfeldt H., Dewji R., Wang D., Robson L., Calvert H. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14:7917-7923.
85. Plummer R., Lorigan P., Steven N., Scott L., Middleton M.R., Wilson R.H., Mulligan E., Curtin N., Wang D., Dewji R., Abbattista A., Gallo J., Calvert H. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother. Pharmacol. 2013, 71:1191-1199.
86. Kaye S.B., Lubinski J., Matulonis U., Ang J.E., Gourley C., Karlan B.Y., Amnon A., Bell-McGuinn K.M., Chen L.M., Friedlander M., Safra T., Vergote I., Wickens M., Lowe E.S., Carmichael J., Kaufman B. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 2012, 30:372-379.
87. Rajan A., Carter C.A., Kelly R.J., Gutierrez M., Kummar S., Szabo E., Yancey M.A., Ji J., Mannargudi B., Woo S., Spencer S., Figg W.D., Giaccone G. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin. Cancer Res. 2012, 18:2344-2351.
88. Khan O.A., Gore M., Lorigan P., Stone J., Greystoke A., Burke W., Carmichael J., Watson A.J., McGown G., Thorncroft M., Margison G.P., Califano R., Larkin J., Wellman S., Middleton M.R. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br. J. Cancer 2011, 104:750-755.
89. Samol J., Ranson M., Scott E., Macpherson E., Carmichael J., Thomas A., Cassidy J. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest. New Drugs 2012, 30:1493-1500.
90. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
91. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
92. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., Ashworth A., Carmichael J., Kaye S.B., Schellens J.H., de Bono J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361:123-134.
93. Steffen J.D., Brody J.R., Armen R.S., Pascal J.M. Structural implications for selective targeting of PARPs. Front. Oncol. 2013, 3:301.
94. Fong P.C., Yap T.A., Boss D.S., Carden C.P., Mergui-Roelvink M., Gourley C., De Greve J., Lubinski J., Shanley S., Messiou C., A'Hern R., Tutt A., Ashworth A., Stone J., Carmichael J., Schellens J.H., de Bono J.S., Kaye S.B. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 2010, 28:2512-2519.
95. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., Lu K., Schmutzler R.K., Matulonis U., Wickens M., Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
96. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., Friedlander M., Arun B., Loman N., Schmutzler R.K., Wardley A., Mitchell G., Earl H., Wickens M., Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
97. Sandhu S.K., Schelman W.R., Wilding G., Moreno V., Baird R.D., Miranda S., Hylands L., Riisnaes R., Forster M., Omlin A., Kreischer N., Thway K., Gevensleben H., Sun L., Loughney J., Chatterjee M., Toniatti C., Carpenter C.L., Iannone R., Kaye S.B., de Bono J.S., Wenham R.M. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013, 14:882-892.
98. O'Shaughnessy J., Osborne C., Pippen J.E., Yoffe M., Patt D., Rocha C., Koo I.C., Sherman B.M., Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 2011, 364:205-214.
99. O'Shaughnessy J., Schwartzberg L.S., Danso M.A., Rugo H.S., Miller K., Yardley D.A., Carlson R.W., Finn R.S., Charpentier E., Freese M., Gupta S., Blackwood-Chirchir A., Winer E.P. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J. Clin. Oncol. 2011, 29. (Suppl.; abstr 1007).
100. Patel A.G., De Lorenzo S.B., Flatten K.S., Poirier G.G., Kaufmann S.H. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin. Cancer Res. 2012, 18:1655-1662.
101. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C., Meier W., Shapira-Frommer R., Safra T., Matei D., Macpherson E., Watkins C., Carmichael J., Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 2012, 366:1382-1392.
102. Johnson N., Li Y.C., Walton Z.E., Cheng K.A., Li D., Rodig S.J., Moreau L.A., Unitt C., Bronson R.T., Thomas H.D., Newell D.R., D'Andrea A.D., Curtin N.J., Wong K.K., Shapiro G.I. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat. Med. 2011, 17:875-882.
103. Ibrahim Y.H., García-García C., Serra V., He L., Torres-Lockhart K., Prat A., Anton P., Cozar P., Guzmán M., Grueso J., Rodríguez O., Calvo M.T., Aura C., Díez O., Rubio I.T., Pérez J., Rodón J., Cortés J., Ellisen L.W., Scaltriti M., Baselga J. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012, 2:1036-1047.
104. Brenner J.C., Ateeq B., Li Y., Yocum A.K., Cao Q., Asangani I.A., Patel S., Wang X., Liang H., Yu J., Palanisamy N., Siddiqui J., Yan W., Cao X., Mehra R., Sabolch A., Basrur V., Lonigro R.J., Yang J., Tomlins S.A., Maher C.A., Elenitoba-Johnson K.S., Hussain M., Navone N.M., Pienta K.J., Varambally S., Feng F.Y., Chinnaiyan A.M. Mechanistic rationale for inhibition of poly(ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011, 19:664-678.
105. Choudhury A., Zhao H., Jalali F., Al Rashid S., Ran J., Supiot S., Kiltie A.E., Bristow R.G. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol. Cancer Ther. 2009, 8:203-213.
106. Chen D.J., Nirodi C.S. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin. Cancer Res. 2007, 13:6555-6560.
107. Li L., Wang H., Yang E.S., Arteaga C.L., Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 2008, 68:9141-9146.
108. Nowsheen S., Cooper T., Stanley J.A., Yang E.S. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One 2012, 7:e46614.
109. Nowsheen S., Bonner J.A., Lobuglio A.F., Trummell H., Whitley A.C., Dobelbower M.C., Yang E.S. Cetuximab augments cytotoxicity with poly (ADP-ribose) polymerase inhibition in head and neck cancer. PLoS One 2011, 6:e24148.
110. Pfäffle H.N., Wang M., Gheorghiu L., Ferraiolo N., Greninger P., Borgmann K., Settleman J., Benes C.H., Sequist L.V., Zou L., Willers H. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res. 2013, 73:6254-6263.
111. Nowsheen S., Cooper T., Bonner J.A., LoBuglio A.F., Yang E.S. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res. 2012, 72:4796-4806.
112. Ganesan S. MYC, PARP1, and chemoresistance: BIN there, done that?. Sci. Signal. 2011, 4:pe15.
113. Chan N., Pires I.M., Bencokova Z., Coackley C., Luoto K.R., Bhogal N., Lakshman M., Gottipati P., Oliver F.J., Helleday T., Hammond E.M., Bristow R.G. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res. 2010, 70:8045-8054.
114. Liu J.F., Tolaney S.M., Birrer M., Fleming G.F., Buss M.K., Dahlberg S.E., Lee H., Whalen C., Tyburski K., Winer E., Ivy P., Matulonis U.A. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur. J. Cancer 2013, 49:2972-2978.
115. Dean E., Middleton M.R., Pwint T., Swaisland H., Carmichael J., Goodege-Kunwar P., Ranson M. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br. J. Cancer 2012, 106:468-474.
116. De Palma M., Hanahan D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol. Oncol. 2012, 6:111-127.
117. Barber L.J., Sandhu S., Chen L., Campbell J., Kozarewa I., Fenwick K., Assiotis I., Rodrigues D.N., Reis Filho J.S., Moreno V., Mateo J., Molife L.R., De Bono J., Kaye S., Lord C.J., Ashworth A. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J. Pathol. 2013, 229:422-429.
118. Bouwman P., Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?. Clin. Cancer Res. 2014, 20:540-547.
119. Lord C.J., Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 2013, 19:1381-1388.
120. Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R., Levine D.A., Boyd J., Reis-Filho J.S., Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1115.
121. Sakai W., Swisher E.M., Karlan B.Y., Agarwal M.K., Higgins J., Friedman C., Villegas E., Jacquemont C., Farrugia D.J., Couch F.J., Urban N., Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120.
122. Norquist B., Wurz K.A., Pennil C.C., Garcia R., Gross J., Sakai W., Karlan B.Y., Taniguchi T., Swisher E.M. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 2011, 29:3008-3015.
123. Ashworth A. Drug resistance caused by reversion mutation. Cancer Res. 2008, 68:10021-10023.
124. Issaeva N., Thomas H.D., Djureinovic T., Djurenovic T., Jaspers J.E., Stoimenov I., Kyle S., Pedley N., Gottipati P., Zur R., Sleeth K., Chatzakos V., Mulligan E.A., Lundin C., Gubanova E., Kersbergen A., Harris A.L., Sharma R.A., Rottenberg S., Curtin N.J., Helleday T. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 2010, 70:6268-6276.
125. Bunting S.F., Callén E., Wong N., Chen H.T., Polato F., Gunn A., Bothmer A., Feldhahn N., Fernandez-Capetillo O., Cao L., Xu X., Deng C.X., Finkel T., Nussenzweig M., Stark J.M., Nussenzweig A. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010, 141:243-254.
126. Bouwman P., Aly A., Escandell J.M., Pieterse M., Bartkova J., van der Gulden H., Hiddingh S., Thanasoula M., Kulkarni A., Yang Q., Haffty B.G., Tommiska J., Blomqvist C., Drapkin R., Adams D.J., Nevanlinna H., Bartek J., Tarsounas M., Ganesan S., Jonkers J. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 2010, 17:688-695.
127. Aly A., Ganesan S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J. Mol. Cell Biol. 2011, 3:66-74.
128. Johnson N., Johnson S.F., Yao W., Li Y.C., Choi Y.E., Bernhardy A.J., Wang Y., Capelletti M., Sarosiek K.A., Moreau L.A., Chowdhury D., Wickramanayake A., Harrell M.I., Liu J.F., D'Andrea A.D., Miron A., Swisher E.M., Shapiro G.I. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:17041-17046.
129. Pennington K.P., Wickramanayake A., Norquist B.M., Pennil C.C., Garcia R.L., Agnew K.J., Taniguchi T., Welcsh P., Swisher E.M. 53BP1 expression in sporadic and inherited ovarian carcinoma: relationship to genetic status and clinical outcomes. Gynecol. Oncol. 2013, 128:493-499.
130. Drost R., Bouwman P., Rottenberg S., Boon U., Schut E., Klarenbeek S., Klijn C., van der Heijden I., van der Gulden H., Wientjens E., Pieterse M., Catteau A., Green P., Solomon E., Morris J.R., Jonkers J. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 2011, 20:797-809.
131. Gottesman M.M., Pastan I., Ambudkar S.V. P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 1996, 6:610-617.
132. Wurzer G., Herceg Z., Wesierska-Gadek J. Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoprotein. Cancer Res. 2000, 60:4238-4244.
133. Rottenberg S., Jaspers J.E., Kersbergen A., van der Burg E., Nygren A.O., Zander S.A., Derksen P.W., de Bruin M., Zevenhoven J., Lau A., Boulter R., Cranston A., O'Connor M.J., Martin N.M., Borst P., Jonkers J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17079-17084.
134. Chiarugi A. A snapshot of chemoresistance to PARP inhibitors. Trends Pharmacol. Sci. 2012, 33:42-48.
135. Jaspers J.E., Kersbergen A., Boon U., Sol W., van Deemter L., Zander S.A., Drost R., Wientjens E., Ji J., Aly A., Doroshow J.H., Cranston A., Martin N.M., Lau A., O'Connor M.J., Ganesan S., Borst P., Jonkers J., Rottenberg S. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013, 3:68-81.
136. Pettitt S.J., Rehman F.L., Bajrami I., Brough R., Wallberg F., Kozarewa I., Fenwick K., Assiotis I., Chen L., Campbell J., Lord C.J., Ashworth A. A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One 2013, 8:e61520.
137. Joosse S.A., van Beers E.H., Tielen I.H., Horlings H., Peterse J.L., Hoogerbrugge N., Ligtenberg M.J., Wessels L.F., Axwijk P., Verhoef S., Hogervorst F.B., Nederlof P.M. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res. Treat. 2009, 116:479-489.
138. Vollebergh M.A., Lips E.H., Nederlof P.M., Wessels L.F., Schmidt M.K., van Beers E.H., Cornelissen S., Holtkamp M., Froklage F.E., de Vries E.G., Schrama J.G., Wesseling J., van de Vijver M.J., van Tinteren H., de Bruin M., Hauptmann M., Rodenhuis S., Linn S.C. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann. Oncol. 2011, 22:1561-1570.
139. Konstantinopoulos P.A., Spentzos D., Karlan B.Y., Taniguchi T., Fountzilas E., Francoeur N., Levine D.A., Cannistra S.A. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 2010, 28:3555-3561.
140. Wysham W.Z., Mhawech-Fauceglia P., Li H., Hays L., Syriac S., Skrepnik T., Wright J., Pande N., Hoatlin M., Pejovic T. BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One 2012, 7:e30042.
141. Cardnell R.J., Feng Y., Diao L., Fan Y.H., Masrorpour F., Wang J., Shen Y., Mills G.B., Minna J.D., Heymach J.V., Byers L.A. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin. Cancer Res. 2013, 19:6322-6328.
142. Abkevich V., Timms K.M., Hennessy B.T., Potter J., Carey M.S., Meyer L.A., Smith-McCune K., Broaddus R., Lu K.H., Chen J., Tran T.V., Williams D., Iliev D., Jammulapati S., FitzGerald L.M., Krivak T., DeLoia J.A., Gutin A., Mills G.B., Lanchbury J.S. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 2012, 107:1776-1782.
143. Willers H., Taghian A.G., Luo C.M., Treszezamsky A., Sgroi D.C., Powell S.N. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol. Cancer Res. 2009, 7:1304-1309.
144. Graeser M., McCarthy A., Lord C.J., Savage K., Hills M., Salter J., Orr N., Parton M., Smith I.E., Reis-Filho J.S., Dowsett M., Ashworth A., Turner N.C. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 2010, 16:6159-6168.
145. Mukhopadhyay A., Elattar A., Cerbinskaite A., Wilkinson S.J., Drew Y., Kyle S., Los G., Hostomsky Z., Edmondson R.J., Curtin N.J. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin. Cancer Res. 2010, 16:2344-2351.
146. Oplustilova L., Wolanin K., Mistrik M., Korinkova G., Simkova D., Bouchal J., Lenobel R., Bartkova J., Lau A., O'Connor M.J., Lukas J., Bartek J. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 2012, 11:3837-3850.
147. Redon C.E., Nakamura A.J., Zhang Y.W., Ji J.J., Bonner W.M., Kinders R.J., Parchment R.E., Doroshow J.H., Pommier Y. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin. Cancer Res. 2010, 16:4532-4542.
148. Balic M., Williams A., Lin H., Datar R., Cote R.J. Circulating tumor cells: from bench to bedside. Annu. Rev. Med. 2013, 64:31-44.
149. Yap T.A., Sandhu S.K., Carden C.P., de Bono J.S. Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J. Clin. 2011, 61:31-49.
150. Gottipati P., Vischioni B., Schultz N., Solomons J., Bryant H.E., Djureinovic T., Issaeva N., Sleeth K., Sharma R.A., Helleday T. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 2010, 70:5389-5398.
151. Turner N.C., Ashworth A. Biomarkers of PARP inhibitor sensitivity. Breast Cancer Res. Treat. 2011, 127:283-286.
152. Kraus W.L., Hottiger M.O. PARP-1 and gene regulation: progress and puzzles. Mol. Aspects Med. 2013, 34:1109-1123.
153. Hakmé A., Wong H.K., Dantzer F., Schreiber V. The expanding field of poly(ADP-ribosyl)ation reactions. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep. 2008, 9:1094-1100.
154. Schiewer M.J., Goodwin J.F., Han S., Brenner J.C., Augello M.A., Dean J.L., Liu F., Planck J.L., Ravindranathan P., Chinnaiyan A.M., McCue P., Gomella L.G., Raj G.V., Dicker A.P., Brody J.R., Pascal J.M., Centenera M.M., Butler L.M., Tilley W.D., Feng F.Y., Knudsen K.E. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012, 2:1134-1149.
155. Pyriochou A., Olah G., Deitch E.A., Szabó C., Papapetropoulos A. Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Int. J. Mol. Med. 2008, 22:113-118.
156. Rajesh M., Mukhopadhyay P., Bátkai S., Godlewski G., Haskó G., Liaudet L., Pacher P. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem. Biophys. Res. Commun. 2006, 350:352-357.
157. Tentori L., Lacal P.M., Muzi A., Dorio A.S., Leonetti C., Scarsella M., Ruffini F., Xu W., Min W., Stoppacciaro A., Colarossi C., Wang Z.Q., Zhang J., Graziani G. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur. J. Cancer 2007, 43:2124-2133.
158. Lacal P.M., Tentori L., Muzi A., Ruffini F., Dorio A.S., Xu W., Arcelli D., Zhang J., Graziani G. Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells. Int. J. Oncol. 2009, 34:861-872.
159. Tentori L., Muzi A., Dorio A.S., Bultrini S., Mazzon E., Lacal P.M., Shah G.M., Zhang J., Navarra P., Nocentini G., Cuzzocrea S., Graziani G. Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. Eur. J. Cancer 2008, 44:1302-1314.
160. Rodríguez M.I., González-Flores A., Dantzer F., Collard J., de Herreros A.G., Oliver F.J. Poly(ADP-ribose)-dependent regulation of Snail1 protein stability. Oncogene 2011, 30:4365-4372.
161. Rodríguez M.I., Peralta-Leal A., O'Valle F., Rodriguez-Vargas J.M., Gonzalez-Flores A., Majuelos-Melguizo J., López L., Serrano S., de Herreros A.G., Rodríguez-Manzaneque J.C., Fernández R., Del Moral R.G., de Almodóvar J.M., Oliver F.J. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet. 2013, 9:e1003531.
162. Martin-Oliva D., Aguilar-Quesada R., O'valle F., Muñoz-Gámez J.A., Martínez-Romero R., García Del Moral R., Ruiz de Almodóvar J.M., Villuendas R., Piris M.A., Oliver F.J. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res. 2006, 66:5744-5756.
163. Verheugd P., Forst A.H., Milke L., Herzog N., Feijs K.L., Kremmer E., Kleine H., Lüscher B. Regulation of NF-κB signalling by the mono-ADP-ribosyltransferase ARTD10. Nat. Commun. 2013, 4:1683.
164. Ju B.G., Solum D., Song E.J., Lee K.J., Rose D.W., Glass C.K., Rosenfeld M.G. Activating the PARP-1 sensor component of the groucho/TLE1 corepressor complex mediates a CaMKinase IIdelta-dependent neurogenic gene activation pathway. Cell 2004, 119:815-829.
165. Butler A.J., Ordahl C.P. Poly(ADP-ribose) polymerase binds with transcription enhancer factor 1 to MCAT1 elements to regulate muscle-specific transcription. Mol. Cell. Biol. 1999, 19:296-306.
166. Hassa P.O., Haenni S.S., Buerki C., Meier N.I., Lane W.S., Owen H., Gersbach M., Imhof R., Hottiger M.O. Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription. J. Biol. Chem. 2005, 280:40450-40464.
167. Leung A., Todorova T., Ando Y., Chang P. Poly(ADP-ribose) regulates post-transcriptional gene regulation in the cytoplasm. RNA Biol. 2012, 9:542-548.
168. Hassa P.O., Haenni S.S., Elser M., Hottiger M.O. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?. Microbiol. Mol. Biol. Rev. 2006, 70:789-829.
169. Cantó C., Sauve A.A., Bai P. Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes. Mol. Aspects Med. 2013, 34:1168-1201.
170. Wang Y., Kim N.S., Haince J.F., Kang H.C., David K.K., Andrabi S.A., Poirier G.G., Dawson V.L., Dawson T.M. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci. Signal. 2011, 4:ra20.
171. Kanai M., Tong W.M., Sugihara E., Wang Z.Q., Fukasawa K., Miwa M. Involvement of poly(ADP-Ribose) polymerase 1 and poly(ADP-Ribosyl)ation in regulation of centrosome function. Mol. Cell. Biol. 2003, 23:2451-2462.
172. Augustin A., Spenlehauer C., Dumond H., Ménissier-De Murcia J., Piel M., Schmit A.C., Apiou F., Vonesch J.L., Kock M., Bornens M., De Murcia G. PARP-3 localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle progression. J. Cell Sci. 2003, 116:1551-1562.
173. Kashima L., Idogawa M., Mita H., Shitashige M., Yamada T., Ogi K., Suzuki H., Toyota M., Ariga H., Sasaki Y., Tokino T. CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation. J. Biol. Chem. 2012, 287:12975-12984.
174. Kops G.J., Weaver B.A., Cleveland D.W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 2005, 5:773-785.
175. Efimova E.V., Mauceri H.J., Golden D.W., Labay E., Bindokas V.P., Darga T.E., Chakraborty C., Barreto-Andrade J.C., Crawley C., Sutton H.G., Kron S.J., Weichselbaum R.R. Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res. 2010, 70:6277-6282.
176. Acosta J.C., Gil J. Senescence: a new weapon for cancer therapy. Trends Cell Biol. 2012, 22:211-219.
177. Meng Y., Efimova E.V., Hamzeh K.W., Darga T.E., Mauceri H.J., Fu Y.X., Kron S.J., Weichselbaum R.R. Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine. Mol. Ther. 2012, 20:1046-1055.
178. Rodier F., Coppé J.P., Patil C.K., Hoeijmakers W.A., Muñoz D.P., Raza S.R., Freund A., Campeau E., Davalos A.R., Campisi J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 2009, 11:973-979.
179. Smith S., de Lange T. Tankyrase promotes telomere elongation in human cells. Curr. Biol. 2000, 10:1299-1302.
180. Cook B.D., Dynek J.N., Chang W., Shostak G., Smith S. Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol. Cell. Biol. 2002, 22:332-342.
181. Seimiya H., Muramatsu Y., Ohishi T., Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 2005, 7:25-37.
182. Cerone M.A., Burgess D.J., Naceur-Lombardelli C., Lord C.J., Ashworth A. High-throughput RNAi screening reveals novel regulators of telomerase. Cancer Res. 2011, 71:3328-3340.
183. Zhang H., Yang M.H., Zhao J.J., Chen L., Yu S.T., Tang X.D., Fang D.C., Yang S.M. Inhibition of tankyrase 1 in human gastric cancer cells enhances telomere shortening by telomerase inhibitors. Oncol. Rep. 2010, 24:1059-1065.
184. Lu H., Lei Z., Lu Z., Lu Q., Lu C., Chen W., Wang C., Tang Q., Kong Q. Silencing tankyrase and telomerase promotes A549 human lung adenocarcinoma cell apoptosis and inhibits proliferation. Oncol. Rep. 2013, 30:1745-1752.
185. Chang P., Coughlin M., Mitchison T.J. Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function. Nat. Cell Biol. 2005, 7:1133-1139.
186. Chang P., Coughlin M., Mitchison T.J. Interaction between Poly(ADP-ribose) and NuMA contributes to mitotic spindle pole assembly. Mol. Biol. Cell 2009, 20:4575-4585.
187. Palazzo L., Della Monica R., Visconti R., Costanzo V., Grieco D. ATM controls proper mitotic spindle structure. Cell Cycle 2014, 13.
188. Dynek J.N., Smith S. Resolution of sister telomere association is required for progression through mitosis. Science 2004, 304:97-100.
189. Hsiao S.J., Smith S. Sister telomeres rendered dysfunctional by persistent cohesion are fused by NHEJ. J. Cell Biol. 2009, 184:515-526.
190. Kim M.K., Smith S. Persistent telomere cohesion triggers a prolonged anaphase. Mol. Biol. Cell 2014, 25:30-40.
191. Smith S., de Lange T. Cell cycle dependent localization of the telomeric PARP, tankyrase, to nuclear pore complexes and centrosomes. J. Cell Sci. 1999, 112(Pt 21):3649-3656.
192. Kim M.K., Dudognon C., Smith S. Tankyrase 1 regulates centrosome function by controlling CPAP stability. EMBO Rep. 2012, 13:724-732.
193. Ozaki Y., Matsui H., Asou H., Nagamachi A., Aki D., Honda H., Yasunaga S., Takihara Y., Yamamoto T., Izumi S., Ohsugi M., Inaba T. Poly-ADP ribosylation of Miki by tankyrase-1 promotes centrosome maturation. Mol. Cell 2012, 47:694-706.
194. McCabe N., Cerone M.A., Ohishi T., Seimiya H., Lord C.J., Ashworth A. Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene 2009, 28:1465-1470.
195. Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A., Charlat O., Wiellette E., Zhang Y., Wiessner S., Hild M., Shi X., Wilson C.J., Mickanin C., Myer V., Fazal A., Tomlinson R., Serluca F., Shao W., Cheng H., Shultz M., Rau C., Schirle M., Schlegl J., Ghidelli S., Fawell S., Lu C., Curtis D., Kirschner M.W., Lengauer C., Finan P.M., Tallarico J.A., Bouwmeester T., Porter J.A., Bauer A., Cong F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620.
196. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
197. C.G.A. Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
198. Lau T., Chan E., Callow M., Waaler J., Boggs J., Blake R.A., Magnuson S., Sambrone A., Schutten M., Firestein R., Machon O., Korinek V., Choo E., Diaz D., Merchant M., Polakis P., Holsworth D.D., Krauss S., Costa M. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 2013, 73:3132-3144.
199. Waaler J., Machon O., Tumova L., Dinh H., Korinek V., Wilson S.R., Paulsen J.E., Pedersen N.M., Eide T.J., Machonova O., Gradl D., Voronkov A., von Kries J.P., Krauss S. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012, 72:2822-2832.
200. Casás-Selves M., Kim J., Zhang Z., Helfrich B.A., Gao D., Porter C.C., Scarborough H.A., Bunn P.A., Chan D.C., Tan A.C., DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012, 72:4154-4164.
201. Yeh T.Y., Sbodio J.I., Tsun Z.Y., Luo B., Chi N.W. Insulin-stimulated exocytosis of GLUT4 is enhanced by IRAP and its partner tankyrase. Biochem. J. 2007, 402:279-290.
202. Dregalla R.C., Zhou J., Idate R.R., Battaglia C.L., Liber H.L., Bailey S.M. Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs. Aging (Albany NY) 2010, 2:691-708.
203. Lord C.J., McDonald S., Swift S., Turner N.C., Ashworth A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 2008, 7:2010-2019.
204. Ekblad T., Camaioni E., Schüler H., Macchiarulo A. PARP inhibitors: polypharmacology versus selective inhibition. FEBS J. 2013, 280:3563-3575.
205. Ang J.E., Gourley C., Powell C.B., High H., Shapira-Frommer R., Castonguay V., De Greve J., Atkinson T., Yap T.A., Sandhu S., Banerjee S., Chen L.M., Friedlander M.L., Kaufman B., Oza A.M., Matulonis U., Barber L.J., Kozarewa I., Fenwick K., Assiotis I., Campbell J., Chen L., de Bono J.S., Gore M.E., Lord C.J., Ashworth A., Kaye S.B. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin. Cancer Res. 2013, 19:5485-5493.